---
schema_version: "secwatch.filing_event.v1"
accession: "0000834365-25-000014"
form_type: "8-K"
ticker: "BLFS"
cik: "0000834365"
company_name: "BIOLIFE SOLUTIONS INC"
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:40:49.082771+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BioLife Solutions Q2 revenue up 29%; raises FY2025 guidance to $100-103M

## Summary
- Total revenue $25.4M (+29% YoY); Cell Processing revenue $23.0M (+28% YoY).
- GAAP net loss $15.8M includes non-cash $15.5M IPR&D charge from PanTHERA acquisition.
- Non-GAAP adjusted net income $0.5M vs. loss of $1.0M a year ago; adjusted EBITDA $6.1M (24% of revenue).
- Raises FY2025 Cell Processing revenue guidance to $91-93M; total revenue guidance to $100-103M.
- Biopreservation media embedded in 16 approved therapies; over 250 ongoing trials, including 30+ Phase III.

## SEC filing metadata
- accession: 0000834365-25-000014
- form_type: 8-K
- ticker: BLFS
- cik: 0000834365
- company_name: BIOLIFE SOLUTIONS INC
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/834365/000083436525000014/0000834365-25-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/834365/000083436525000014/blfs-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000834365-25-000014
- JSON: https://secwatch.observer/filing/0000834365-25-000014.json
- Plain text: https://secwatch.observer/filing/0000834365-25-000014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.